What Is NR

Nicotinamide riboside (NR) is a naturally occurring form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme required by every cell for energy production, DNA repair, and signaling. Found in trace amounts in milk and certain foods, NR is primarily consumed as a supplement to raise intracellular NAD+ levels. It is converted into NAD+ through a two-step enzymatic process that is distinct from the pathways used by other B3 forms such as niacin or nicotinamide.

NAD+ concentrations decline significantly with age, falling by roughly half between young adulthood and middle age in some tissue measurements. This decline is implicated in reduced mitochondrial function, impaired DNA repair capacity, diminished sirtuin activity, and increased susceptibility to metabolic dysfunction. Because NAD+ sits at the intersection of so many cellular maintenance processes, its depletion is considered one of the mechanistic drivers behind multiple hallmarks of aging, including genomic instability, mitochondrial dysfunction, and altered nutrient sensing.

NR matters to the longevity field because it offers a targeted, orally bioavailable way to replenish this declining coenzyme. Unlike direct NAD+ supplementation, which has poor oral bioavailability due to rapid degradation in the gut, NR can cross cell membranes and be enzymatically converted to NAD+ inside cells. This makes it a practical candidate for addressing NAD+ depletion at scale, though whether restoring youthful NAD+ levels in humans translates to measurable healthspan extension remains an open question.

Once ingested, NR is absorbed through the intestinal lining and enters the bloodstream. Inside cells, nicotinamide riboside kinases (NRK1 and NRK2) phosphorylate NR into nicotinamide mononucleotide (NMN). A second enzyme, nicotinamide mononucleotide adenylyltransferase (NMNAT), then converts NMN into NAD+. This two-step NRK pathway is notable because it bypasses the enzyme NAMPT, which is the rate-limiting step in the salvage pathway that recycles nicotinamide back into NAD+. By entering downstream of this bottleneck, NR can potentially boost NAD+ production even when NAMPT activity is reduced by age or metabolic stress.

The NAD+ produced from NR participates in hundreds of enzymatic reactions. It serves as a substrate for sirtuins, a family of deacetylase enzymes that regulate gene expression, mitochondrial biogenesis, and inflammatory signaling. It is also consumed by poly(ADP-ribose) polymerases (PARPs), which are central to DNA damage repair. Additionally, NAD+ feeds the enzyme CD38, which uses it to generate calcium-signaling molecules. The competition among these NAD+-consuming enzymes means that total NAD+ availability directly affects the cell's capacity to maintain and repair itself.

Beyond direct enzymatic roles, NAD+ influences the ratio of its oxidized to reduced forms (NAD+/NADH), which is a core regulator of cellular redox balance and metabolic flux through glycolysis, the citric acid cycle, and oxidative phosphorylation. When NAD+ levels are low, cells shift toward less efficient metabolic states, accumulate damage, and send pro-inflammatory signals. Restoring NAD+ through NR supplementation aims to reverse this metabolic shift and re-enable the cellular maintenance programs that decline with age.

NR is commercially available primarily as nicotinamide riboside chloride (marketed under trade names such as Niagen), which is the form used in most clinical trials. It is sold as oral capsules, tablets, and occasionally in powder form for sublingual use. Some formulations combine NR with pterostilbene, trimethylglycine (TMG), or other cofactors intended to support methylation and sirtuin activity alongside NAD+ production.

Oral bioavailability of NR has been demonstrated in multiple pharmacokinetic studies, with peak blood NAD+ increases occurring within hours of ingestion. Unlike intravenous NAD+ infusions, oral NR does not require clinical administration and can be taken at home. Some manufacturers offer delayed-release or enteric-coated capsules to reduce gastric degradation, though the clinical advantage of these formats over standard capsules has not been established in head-to-head trials. Stability can vary by formulation; NR is sensitive to heat and moisture, so storage conditions matter for potency retention.

Human trials have used dosing ranges from 100 mg to 2,000 mg daily. The most commonly studied dose is 250 to 1,000 mg per day, which consistently produces measurable increases in whole-blood NAD+. Dose-response studies suggest that NAD+ elevation plateaus at higher doses, meaning that doubling intake does not necessarily double the effect. This ceiling likely reflects the rate at which NRK enzymes can phosphorylate NR and the speed at which NAD+ is consumed by PARPs, sirtuins, and CD38.

Splitting the daily dose between morning and evening may help maintain more stable NAD+ levels throughout the day, though this approach has not been directly compared to single-dose administration in controlled studies. Some practitioners recommend pairing NR with a methyl donor such as TMG, because NAD+ metabolism through nicotinamide clearance consumes methyl groups. The clinical relevance of methyl donor co-supplementation is plausible mechanistically but has not been validated in rigorous trials. Individual response may vary based on baseline NAD+ status, age, metabolic health, and the activity levels of competing NAD+-consuming enzymes.

The most important quality marker for NR supplements is the use of the patented Niagen form of nicotinamide riboside chloride, which is the specific compound studied in clinical trials and holds FDA Generally Recognized as Safe (GRAS) status. Products listing generic nicotinamide riboside without specifying the chloride salt or referencing the Niagen trademark may contain less characterized material. Third-party testing by organizations such as NSF International, USP, or Informed Sport provides independent verification of purity, potency, and absence of contaminants including heavy metals and microbial contamination.

Because NR is sensitive to degradation from heat, light, and moisture, look for products packaged in opaque, sealed bottles with desiccant packets. A certificate of analysis (COA) from the manufacturer or a third-party lab should confirm that the product contains the labeled dose of NR and is free from significant levels of nicotinamide (a common degradation product). Manufacturers who publish batch-specific COAs and conduct stability testing over the product's shelf life offer a higher degree of transparency. Avoid products making disease treatment claims, as these violate supplement labeling regulations and often correlate with lower manufacturing standards.

NR has a stronger human clinical trial record than many longevity supplements. Multiple randomized, placebo-controlled trials have confirmed that oral NR supplementation at doses up to 2,000 mg per day reliably increases blood and tissue NAD+ levels in a dose-dependent fashion. A trial in older adults demonstrated improved NAD+ metabolome markers and reduced systemic inflammation. Another study in overweight adults showed trends toward improved metabolic parameters, though the changes did not always reach statistical significance. Trials in heart failure patients have found that NR raises NAD+ in cardiac tissue, with some functional improvements observed.

The gap between biochemical proof of concept and clinical endpoints remains the central limitation. While animal studies (primarily in mice) have shown compelling benefits for mitochondrial function, insulin sensitivity, neurodegeneration, and even lifespan in certain disease models, no human trial has yet demonstrated that NR extends lifespan, reverses biological aging as measured by epigenetic clocks, or prevents age-related disease. Most human studies have been small, lasting weeks to months, and powered to detect NAD+ changes rather than hard clinical outcomes. Several larger, longer-duration trials are in progress, and their results will substantially clarify whether biochemical NAD+ restoration translates into the kind of functional improvements observed in animal research.

NR is generally well tolerated at commonly studied doses, with the most frequently reported side effects being mild nausea, headache, and occasional flushing (less severe than with niacin). At very high doses (above 2,000 mg per day), some participants have reported gastrointestinal discomfort and skin tingling. A theoretical concern exists around cancer biology: because NAD+ supports the metabolism of all rapidly dividing cells, there is ongoing debate about whether raising NAD+ could inadvertently fuel existing tumors. Preclinical data on this question is mixed, with some studies suggesting protective effects and others showing context-dependent risks. Individuals with known malignancies should discuss NR use with their oncologist. Long-term safety data beyond six months of continuous use remains sparse, and drug interactions have not been comprehensively characterized.